AMCP Market Insights: As Psychedelic Therapies Advance, Payers Prepare for Coverage and Access Challenges

Alexandria, Va. — As psychedelic-assisted therapies move closer to potential use in treating treatment-resistant depression (TRD), health plans, pharmacy benefit managers, and other managed care stakeholders are beginning to evaluate how these therapies could fit within existing coverage, reimbursement, and care delivery models. A new Journal of Managed Care + Specialty Pharmacy (JMCP) supplement from AMCP Market Insights provides a roadmap for many of the questions payers may face as innovative therapies enter the depression treatment landscape.

The supplement, AMCP Market Insights: Optimizing Managed Care Approaches to Treatment-Resistant Depression, summarizes findings from a March 2026 roundtable that brought together health plan leaders, integrated delivery networks, pharmacy benefit managers, and clinical experts to discuss TRD, emerging evidence for psilocybin, and the implications for managed care decision-makers. 

TRD remains a significant challenge for patients, caregivers, providers, and health plans. Participants agreed that substantial unmet needs persist despite multiple available treatment options and that managed care organizations must balance the potential promise of innovative therapies with ongoing questions regarding evidence, operational readiness, and long-term value.

"Managed care stakeholders recognize the urgent need for additional treatment options for patients living with treatment-resistant depression," said [AMCP spokesperson]. "At the same time, organizations are evaluating how emerging therapies could be implemented in ways that support patient access, maintain high-quality care, and ensure responsible use of health care resources."

Among the supplement’s key findings:

• Payers see significant unmet need in TRD and view reducing barriers to care as a priority. 
• Stakeholders expressed interest in the potential of psilocybin-assisted therapy but identified important unanswered questions regarding comparative effectiveness, appropriate patient selection, treatment durability, and cost-effectiveness. 
• Managed care organizations are evaluating how specialized treatment administration, observation requirements, and post-treatment support could affect coverage and care delivery.
• Participants identified behavioral health workforce capacity and provider network readiness as major considerations for ensuring equitable patient access if psychedelic-assisted therapies become available.
• Health plans are likely to look toward existing experience with therapies such as ketamine and esketamine when developing future coverage policies and access strategies. 

The supplement notes that payer decision-makers are particularly focused on practical implementation questions, including provider network adequacy, reimbursement models, coordination across medical, pharmacy, and behavioral health benefits, and the evidence needed to support coverage decisions. Participants also emphasized the importance of stakeholder education, collaboration, and additional data generation as the evidence base continues to evolve. 

While the discussion centered on treatment-resistant depression, the findings may have broader relevance as other psychedelic-assisted therapies and novel mental health treatments advance through development and regulatory review. The publication provides insight into how managed care organizations are preparing to evaluate these innovations while balancing access, affordability, quality, and patient safety. 

The full supplement, AMCP Market Insights: Optimizing Managed Care Approaches to Treatment-Resistant Depression, is available in the September 2026 supplement issue of JMCP.